Literature DB >> 26735329

Lipid peroxidation biomarkers in adolescents with or at high-risk for bipolar disorder.

Gustavo Scola1, Robert K McNamara2, Paul E Croarkin3, Jarrod M Leffler3, Kathryn R Cullen4, Jennifer R Geske5, Joanna M Biernacka5, Mark A Frye3, Melissa P DelBello2, Ana C Andreazza6.   

Abstract

BACKGROUND: Prior work suggests that adult bipolar disorder (BD) is associated with increased oxidative stress and inflammation. This exploratory study examined markers of lipid and protein oxidation and inflammation in adolescents with and at varying risk for BD type I (BD-I).
METHODS: Blood was obtained from four groups of adolescents (9-20 years of age): (1) healthy comparison subjects with no personal or family history of psychiatric disorders (n=13), (2) subjects with no psychiatric diagnosis and at least one parent with BD-I ('high-risk', n=15), (3) subjects with at least one parent with BD-I and a diagnosis of depressive disorder not-otherwise-specified ('ultra-high-risk', n=20), and (4) first-episode patients exhibiting mixed or manic symptoms that received a diagnosis of BD-I (n=16). Plasma levels of lipid peroxidation (LPH, 4-HNE, 8-ISO), protein carbonyl, and inflammation (IL-1α-β, IL-6, IL-10, IFNγ, TNFα) were assessed using analysis of variance and covariance models.
RESULTS: LPH was lower in adolescents with fully syndromal BD than controls, while LPH levels in the at-risk groups were between healthy controls and fully syndromal BD. Post-hoc analysis showed a non-significant increase in the (4-HNE+8-ISO)/LPH ratio suggesting a potential conversion of LPH into late-stage markers of lipid peroxidation. There were no significant differences among protein carbonyl content and inflammatory markers.
CONCLUSIONS: In adolescents, fully syndromal BD is associated with significant reductions in LPH levels, and LPH levels decrease along the spectrum of risk for BD-I. Quantifying lipid peroxidation in longitudinal studies may help clarify the role of LPH in BD risk progression.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adolescent bipolar disorder; At-risk adolescents; Lipid peroxidation; Oxidative stress markers

Mesh:

Substances:

Year:  2015        PMID: 26735329      PMCID: PMC5549852          DOI: 10.1016/j.jad.2015.12.020

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  54 in total

1.  Differential regulation of c-jun and CREB by acrolein and 4-hydroxynonenal.

Authors:  Subbiah Pugazhenthi; Ketaki Phansalkar; Gerald Audesirk; Anne West; Leigh Cabell
Journal:  Free Radic Biol Med       Date:  2005-09-02       Impact factor: 7.376

Review 2.  Preventative strategies for early-onset bipolar disorder: towards a clinical staging model.

Authors:  Robert K McNamara; Jayasree J Nandagopal; Stephen M Strakowski; Melissa P DelBello
Journal:  CNS Drugs       Date:  2010-12       Impact factor: 5.749

3.  Peroxisome-proliferator-activated receptors regulate redox signaling in the cardiovascular system.

Authors:  Teayoun Kim; Qinglin Yang
Journal:  World J Cardiol       Date:  2013-06-26

Review 4.  Inflammation in children and adolescents with neuropsychiatric disorders: a systematic review.

Authors:  Rachel H B Mitchell; Benjamin I Goldstein
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-12-16       Impact factor: 8.829

5.  Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders.

Authors:  Benjamin I Goldstein; Katelyn A Collinger; Francis Lotrich; Anna L Marsland; Mary-Kay Gill; David A Axelson; Boris Birmaher
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-10       Impact factor: 2.576

Review 6.  A comprehensive review and model of putative prodromal features of bipolar affective disorder.

Authors:  O D Howes; S Lim; G Theologos; A R Yung; G M Goodwin; P McGuire
Journal:  Psychol Med       Date:  2010-09-14       Impact factor: 7.723

7.  Lipid peroxidation end product 4-hydroxy-trans-2-nonenal triggers unfolded protein response and heme oxygenase-1 expression in PC12 cells: Roles of ROS and MAPK pathways.

Authors:  Meng-Han Lin; Jui-Hung Yen; Ching-Yi Weng; Lisu Wang; Choi-Lan Ha; Ming-Jiuan Wu
Journal:  Toxicology       Date:  2013-11-28       Impact factor: 4.221

8.  Modulation of keratinocyte expression of antioxidants by 4-hydroxynonenal, a lipid peroxidation end product.

Authors:  Ruijin Zheng; Diane E Heck; Vladimir Mishin; Adrienne T Black; Michael P Shakarjian; Ah-Ng Tony Kong; Debra L Laskin; Jeffrey D Laskin
Journal:  Toxicol Appl Pharmacol       Date:  2014-01-11       Impact factor: 4.219

Review 9.  The proximal prodrome to first episode mania--a new target for early intervention.

Authors:  Philippe Conus; Janine Ward; Karen T Hallam; Nellie Lucas; Craig Macneil; Patrick D McGorry; Michael Berk
Journal:  Bipolar Disord       Date:  2008-07       Impact factor: 6.744

Review 10.  Current state of biomarkers in bipolar disorder.

Authors:  Gustavo Scola; Ana Cristina Andreazza
Journal:  Curr Psychiatry Rep       Date:  2014-12       Impact factor: 5.285

View more
  15 in total

Review 1.  Polyunsaturated fatty acids and recurrent mood disorders: Phenomenology, mechanisms, and clinical application.

Authors:  Erik Messamore; Daniel M Almeida; Ronald J Jandacek; Robert K McNamara
Journal:  Prog Lipid Res       Date:  2017-01-06       Impact factor: 16.195

2.  Meta-analysis of erythrocyte polyunsaturated fatty acid biostatus in bipolar disorder.

Authors:  Robert K McNamara; Jeffrey A Welge
Journal:  Bipolar Disord       Date:  2016-04-18       Impact factor: 6.744

Review 3.  Insulin resistance takes center stage: a new paradigm in the progression of bipolar disorder.

Authors:  Cynthia V Calkin
Journal:  Ann Med       Date:  2019-08-27       Impact factor: 4.709

4.  Serum phosphatidylinositol as a biomarker for bipolar disorder liability.

Authors:  Emma Em Knowles; Peter J Meikle; Kevin Huynh; Harald Hh Göring; Rene L Olvera; Samuel R Mathias; Ravi Duggirala; Laura Almasy; John Blangero; Joanne E Curran; David C Glahn
Journal:  Bipolar Disord       Date:  2017-02-23       Impact factor: 6.744

5.  Metabolomic Identification of Serum Exosome-Derived Biomarkers for Bipolar Disorder.

Authors:  Yang Du; Ji-Hui Dong; Lei Chen; Hua Liu; Guang-En Zheng; Guang-Yang Chen; Yong Cheng
Journal:  Oxid Med Cell Longev       Date:  2022-01-10       Impact factor: 6.543

Review 6.  Neurobiology of Risk for Bipolar Disorder.

Authors:  Ayşegül Özerdem; Deniz Ceylan; Güneş Can
Journal:  Curr Treat Options Psychiatry       Date:  2016-10-20

Review 7.  The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research.

Authors:  Benjamin I Goldstein; Boris Birmaher; Gabrielle A Carlson; Melissa P DelBello; Robert L Findling; Mary Fristad; Robert A Kowatch; David J Miklowitz; Fabiano G Nery; Guillermo Perez-Algorta; Anna Van Meter; Cristian P Zeni; Christoph U Correll; Hyo-Won Kim; Janet Wozniak; Kiki D Chang; Manon Hillegers; Eric A Youngstrom
Journal:  Bipolar Disord       Date:  2017-09-25       Impact factor: 6.744

8.  Lipid Peroxidation Markers in Coronary Artery Disease Patients with Possible Vascular Mild Cognitive Impairment.

Authors:  Ivonne Suridjan; Nathan Herrmann; Alex Adibfar; Mahwesh Saleem; Ana Andreazza; Paul I Oh; Krista L Lanctôt
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 9.  Challenges and developments in research of the early stages of bipolar disorder.

Authors:  Elisa Brietzke; Adriane R Rosa; Mariana Pedrini; Mariane N Noto; Flavio Kapczinski; Jan Scott
Journal:  Braz J Psychiatry       Date:  2016-08-11       Impact factor: 2.697

10.  Association Between Sphingolipids and Cardiopulmonary Fitness in Coronary Artery Disease Patients Undertaking Cardiac Rehabilitation.

Authors:  Mahwesh Saleem; Nathan Herrmann; Adam Dinoff; Susan Marzolini; Michelle M Mielke; Ana Andreazza; Paul I Oh; Swarajya Lakshmi Vattem Venkata; Norman J Haughey; Krista L Lanctôt
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-03-09       Impact factor: 6.591

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.